ESTRO 2024 - Abstract Book

S2629

Clinical - Urology

ESTRO 2024

following variables were included as independent predictors pT3-pT4 (HR: 1.51, 95% CI 1.24-1.85, p<0.05), ISUP 4-5 (HR: 1.57, 95% CI 1.30-1.90, p<0.05), time from surgery to sRT < 12 months (HR: 1.68, 95% CI 1.37-2.06, p<0.05) and administrator of hormonal therapy (HT) during SRT (HR: 0.76, 95% CI 0.60-0.97, p<0.05).

Fig. 1 – Kaplan Meier of biochemical recurrence free survival (BRFS)

Clinical recurrence free survival (CRFS) was assessed, analysing a total of 494 events (30%) with a median time of 3.26 (IQR 1.70-5.13) years (Fig. 2). At multivariate analyses for CPFS, the following variables were identified as independent predictors: pT3-pT4 (HR: 1.34, 95% CI 1.07-1.67, p < 0.05), ISUP4-5 (HR: 1.66, 95% CI 1.35-2.05, p < 0.05), time from surgery to sRT < 12 months (HR: 1.75, 95% CI 1.41-2.21, p < 0.05).

Fig. 2 - Kaplan Meier of clinical recurrence free survival (CRFS)

Distant metastasis free survival (DMFS) was assessed, finding a total of 222 events (14%) with a median time of 3.77 (IQR 2.08-5.79) years (Fig. 3). At multivariate analyses for DMFS, the following variables were identified as independent predictors: pT3-pT4 (HR: 1.65, 95% CI 1.16-2.35, p < 0.05), ISUP4-5 (HR: 1.79, 95% CI 1.31-2.43, p < 0.05), time from sRT < 12 months (HR: 1.54, 95% CI 1.10-2.17, p < 0.05) and pelvis involvement in the salvage radiotherapy treatment (HR: 1.58, 95% CI 1.15-2.16, p < 0.05).